Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:305
Name carcinoma
Definition A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids DOID:6570 DOID:2428
Path disease disease of cellular proliferation cancer cell type cancer carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown DSP107 carcinoma not applicable detail...
Unknown unknown Cetuximab + DSP107 carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Recruiting USA 0
NCT01148849 Phase I Margetuximab-cmkb Safety Study of MGAH22 in HER2-positive Carcinomas Active, not recruiting USA 1
NCT01427322 Phase I Lapatinib Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease Terminated USA 0
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed 0
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting USA 8
NCT02637531 Phase I Pembrolizumab IPI-549 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Active, not recruiting USA 0
NCT02648490 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Completed USA 1
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting USA 0
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT03094169 Phase I AVID100 AVID100 in Advanced Epithelial Carcinomas Active, not recruiting USA 0
NCT03391973 Phase II Pembrolizumab Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) Recruiting CAN 0
NCT03396471 Phase II Pembrolizumab Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary Recruiting USA 0
NCT03436563 Phase Ib/II M7824 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Recruiting USA 0
NCT03570619 Phase II Ipilimumab + Nivolumab Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (IMPACT) Recruiting USA 0
NCT03852511 Phase I NG-350A First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE) Recruiting USA 0
NCT04053283 Phase I NG-641 First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector Recruiting USA 0
NCT04147819 Phase I BAY2701439 A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein Recruiting USA 1
NCT04441099 Phase Ib/II NBE-002 NBE-002 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT04478279 Phase Ib/II ST-101 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT04520711 Phase I CDX-1140 + Pembrolizumab + TSA/TAA-specific TCR engineered T cells Study of Adoptively Transferred, Gene-engineered T Cells With CD40 Activation and PD-1 Blockade in Incurable Cancers Not yet recruiting USA 0
NCT04648826 Phase Ib/II Azacitidine + M7824 Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies Not yet recruiting USA 0